Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Total Current Liabilities (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Total Current Liabilities data on record, last reported at $23.9 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 51.85% year-over-year to $23.9 million; the TTM value through Sep 2025 reached $23.9 million, up 51.85%, while the annual FY2024 figure was $18.5 million, 91.59% up from the prior year.
  • Total Current Liabilities reached $23.9 million in Q3 2025 per DNTH's latest filing, up from $20.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $23.9 million in Q3 2025 and bottomed at $4.0 million in Q2 2023.
  • Average Total Current Liabilities over 4 years is $12.9 million, with a median of $12.9 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: plummeted 64.16% in 2023, then soared 148.61% in 2024.
  • A 4-year view of Total Current Liabilities shows it stood at $8.2 million in 2022, then grew by 17.09% to $9.6 million in 2023, then soared by 91.59% to $18.5 million in 2024, then rose by 29.28% to $23.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $23.9 million in Q3 2025, $20.1 million in Q2 2025, and $17.0 million in Q1 2025.